Evidence map›Paper›PMID 42432252›Full record

ArticleCell death and differentiation2026

UbiDash: A UPS proteomic atlas for tissue-aware degrader design.

Tania J González-Robles, Paul Sastourné, Marisa Triola, Maha Khan, Áron Bartha, Jeffrey Estrada, Yadira M Soto-Feliciano, Benjamin G Neel, David Fenyö, Michele Pagano and 1 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Cell death and differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Tania J González-RoblesDivision of Precision Medicine, Department of Medicine, NYU Grossman School of Medicine, New York, NY, 10016, USA.ORCID http://orcid.org/0000-0001-9292-382X
Paul Sastourné *Division of Precision Medicine, Department of Medicine, NYU Grossman School of Medicine, New York, NY, 10016, USA.
Marisa Triola *Division of Precision Medicine, Department of Medicine, NYU Grossman School of Medicine, New York, NY, 10016, USA.
Maha KhanDivision of Precision Medicine, Department of Medicine, NYU Grossman School of Medicine, New York, NY, 10016, USA.
Áron BarthaDepartment of Bioinformatics, Semmelweis University, Budapest, 1094, Hungary.ORCID http://orcid.org/0000-0003-0395-243X
Jeffrey EstradaDepartment of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, 10016, USA.
Yadira M Soto-FelicianoDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.ORCID http://orcid.org/0000-0002-8523-7917
Benjamin G NeelDivision of Precision Medicine, Department of Medicine, NYU Grossman School of Medicine, New York, NY, 10016, USA.ORCID http://orcid.org/0000-0002-9589-585X
David FenyöInstitute for System Genetics, NYU Grossman School of Medicine, New York, NY, 10016, USA.
Michele PaganoLaura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY, 10016, USA. Michele.Pagano@nyulangone.org.ORCID http://orcid.org/0000-0003-3210-2442
Kelly V RugglesDivision of Precision Medicine, Department of Medicine, NYU Grossman School of Medicine, New York, NY, 10016, USA. Kelly.Ruggles@nyulangone.org.

Funding

Training Program in Cell BiologyT32GM136542 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SMITH, SUSAN · 2020 to 2024
$3.0M
Division of Cancer Prevention, National Cancer Institute (NCI Division of Cancer Prevention) 1U54CA263001-01A1Howard Hughes Medical Institute (HHMI) GT15758U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) T32GM136542
6 · The paper itself

Abstract

Targeted protein degradation repurposes endogenous E3 ubiquitin ligases to eliminate disease-driving proteins, yet the ligase toolkit deployed clinically remains narrow and largely tissue-agnostic. To support rational expansion of this toolkit, we built a harmonized pan-tissue proteomic atlas of the ubiquitin-proteasome system (UPS) by integrating four major resources: (1) CPTAC tumor and normal-adjacent tissues, (2) PRIDE healthy tissues, (3) the Pan-Cancer Proteome Atlas (TPCPA), and (4) the Cancer Cell Line Encyclopedia (CCLE). The resulting atlas spans 20 distinct tissue contexts and quantifies 5998 proteins, including 473 UPS components and 181 E3 ligases. Cross-resource validation confirmed successful harmonization while maintaining biological signal. We then derived a sample-level relative rank score (RRS) for every quantified UPS protein and identified 139 E3 ligases (of 181 detected) as being significantly tissue- or tumor-specific, including XIAP in lung cancer, KLHL7 in female-specific malignancies, and FBXL18 in head-and-neck and brain tumors. To enable broad accessibility, we developed UbiDash ( https://ruggleslab.shinyapps.io/UbiDash/ ), an interactive R Shiny platform that supports queries of UPS expression, mutation effects, protein co-regulation, and clinical associations. Together, the atlas and UbiDash provide a tissue-aware framework for ligase prioritization and rational degrader design that complements the mechanistic mutation- and lineage-driven UPS analyses described in our companion manuscript [1].

Identifiers

PMID42432252

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.